Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Mastering the correct use of Balversais the first step to ensuring efficacy and safety, so let's dive into its detailed medication guidelines.How to use BalversaThe use of Balv···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：381
In-depth analysis of the treatment of Balversa, the primary concern is its recommended dose, which is directly related to the safety and effect of treatment.What is the recommended···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：453
Alpelisib effectively treats patients with HR/HER2- breast cancer harboring PIK3CA mutations by inhibiting the PI3Kα signaling pathway; The precise targeting effect greatly reduces···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：470
As the first PI3Kα inhibitor, Alpelisib has shown significant efficacy in the treatment of HR/HER2- breast cancer. By targeting PIK3CA mutations, drugs can prolong the progression-···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：487
Alpelisib, approved in 2019, has a unique efficacy against PIK3CA mutant breast cancer. Alpelisib has become a key drug for the treatment of advanced breast cancer by blocking the ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：503
Alpelisib is the first PI3K inhibitor specifically for PIK3CA-mutated breast cancer and can be used in combination with fulvestrant to significantly prolong progression-free surviv···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：453
Alpelisib was approved by the FDA in 2019 for the treatment of breast cancer patients with HR/HER2- and PIK3CA mutations. By inhibiting the PI3K signaling pathway, Alpelisib effect···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：470
Alpelisib is the first PI3Kα inhibitor to be used in combination with fulvestrant for the treatment of HR/HER2- breast cancer. By targeting the PIK3CA mutation, Alpelisib significa···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：516
Balversais a new target anti-cancer star, specializing in FGFR-positive cancers, providing patients with precision treatment options, although effective, it is necessary to pay att···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：421
Balversa, an innovative anti-cancer targeted drug, accurately snipes FGFR-positive tumors and opens up new hope for patients with advanced cancer.What diseases is Balversasuitable ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：446
Balversa is an innovative targeted therapy that effectively inhibits the growth of cancer cells for FGFR-positive tumors, bringing new treatment options to patients, but they need ···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：454
Balversa, a new targeted anti-cancer drug, provides new treatment hope for patients with advanced cancer by precisely inhibiting the FGFR signaling pathway.Is Balversaexpensive? Ho···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：403
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended：[list:visits]2026-30-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
